VRTX · News · 20261103N

Guidance / Outlook

VERTEX PHARMACEUTICALS INC / MA · 2026-11-03 · Importance 51 · Surprise 60

Vertex raised its full-year 2026 revenue guidance to $13.15 billion–$13.25 billion after reporting third-quarter revenue of $3.44 billion. The revised outlook reflects the addition of Crinetics Pharmaceuticals, acquired in September 2026, as well as contributions from Vertex’s existing and newer therapies. The reports do not provide a revised margin or capital-expenditure outlook.

Key facts

• Vertex expects full-year revenue of $13.15 billion to $13.25 billion. source
• Vertex's Q3 2026 revenue was $3.44 billion versus an estimate of $3.41 billion, and FY2026 revenue guidance was $13.15 billion to $13.25 billion. source
• Vertex raised its full-year 2026 sales guidance. source
• Vertex raised full-year revenue guidance, which the report attributed primarily to the Crinetics acquisition rather than organic growth. source